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Abstract 
Diabetes mellitus is a major, global problem. Among the numerous complications of diabetes, there is increasing concern over the coexisting 
heart failure. Metformin is the most frequently used oral antidiabetic drug that is considered to be safe and effective in the management of 
type 2 diabetes mellitus. Since the publication of the UK Prospective Diabetes Study, it has been suggested that metformin might improve 
cardiovascular prognoses. Results from available studies have shown that metformin therapy in patients with type 2 diabetes mellitus 
and heart failure was associated with improved clinical outcomes when compared with other oral antidiabetic agents, insulin, or lifestyle 
management. However, there have been no randomized controlled trials evaluating the influence of metformin use on clinical outcomes 
in patients with type 2 diabetes mellitus and heart failure. New evidence from large cardiovascular outcome trials that showed a reduc-
tion in heart failure hospitalization for SGLT2 inhibitors caused changes in recommendations on the management of hyperglycaemia. 
Currently, the European Society of Cardiology recommends sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes 
mellitus and heart failure or at high risk for heart failure, as a first choice in drug naïve patients, or as a second drug if the patient is al-
ready on metformin. The aim of our study is to review the current state of knowledge about the position of metformin in the treatment 
of patients with type 2 diabetes mellitus and heart failure. (Endokrynol Pol 2021; 72 (2): 163–170)
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Introduction 
Diabetes mellitus is a significant medical, social, and eco-
nomic problem. Data from the International Diabetes 
Federation show that diabetes affects 463 million adults 
worldwide, and it is estimated that one in two people 
living with diabetes are unaware of their condition [1]. 
In Poland, the number of people suffering from diabetes 
amounted to 2.533 million in 2017 [2]. Among the nu-
merous health complications of diabetes mellitus there 
is increasing concern over a previously undervalued 
issue: coexisting heart failure (HF). 
In 2020, on the 56th annual meeting of the European 
Association for the Study of Diabetes (EASD), the CAP-
TURE study on the prevalence of cardiovascular disease 
(CVD) involving 9823 patients with type 2 diabetes mel-
litus (T2DM) from 13 countries was presented. Overall, 
34.8% of participants had CVD, and 2.4% suffered from 
HF [3]. In the analysis from the CVD-REAL 2 multina-
tional cohort study on the risk of cardiovascular (CV) 
events and death in 38,6248 adult patients with T2DM, 
newly initiated on sodium-glucose co-transporter 2 
(SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP-4) 
inhibitors, HF was present in 7% of patients at base-
line [4]. The prevalence of HF in diabetic patients in 
real-world studies ranges from 5 to 6.8% [5, 6].
Metformin is the most frequently used oral an-
tidiabetic drug that is considered to be safe and ef-
fective in the management of T2DM [7]. It acts as 
a glucose-lowering agent through the decrease of 
hepatic glucose production, as well as lowering insulin 
resistance in peripheral tissues. Besides its neutral effect 
on body weight and its positive impact on lipidogram, 
metformin’s influence on the CV system seems to be 
cardioprotective, because it has a beneficial impact on 
the vascular wall and clotting system parameters [8]. 
Since the publication of UK Prospective Diabetes Study 
34 (UKPDS 34), metformin has emerged as a drug that 
seems to decrease the risk of diabetes-related endpoints, 
including macrovascular and microvascular complica-
tions, in overweight patients with T2DM. The results 
of UKPDS 34 showed that patients who were allocated 
metformin had a 32% lower risk (p = 0.0023) of devel-
oping any diabetes-related endpoint, a 36% lower risk 
Endokrynologia Polska
DOI: 10.5603/EP.a2021.0033
Volume/Tom 72; Number/Numer 2/2021
ISSN 0423–104X, e-ISSN 2299–8306
Zofia Kulaczkowska, 3rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University 
of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland; e-mail: zosiakulaczkowska@gmail.com
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles  
and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
164





pared with patients not treated with insulin-sensitizing 
drugs (n = 12069). There was no difference in all-cause 
hospitalization between insulin-sensitizing agents, 
although patients receiving metformin had a lower 
risk of hospitalization for HF, while patients receiving 
thiazolidinediones had a higher risk of hospitaliza-
tion for HF when compared with the therapy without 
an insulin-sensitizing drug [13].
MacDonald et al. designed a case-control study 
that assessed treatment with metformin in patients 
newly diagnosed with HF and T2DM, during a median 
follow-up of 2.8 years. A comparison group consisted 
of individuals without an antidiabetic drug in their 
therapy. Metformin monotherapy was associated with 
lower all-cause mortality when compared with patients 
not exposed to antidiabetic therapy [14].
In the analysis of 6185 ambulatory patients with HF 
and T2DM, 1561 participants treated with metformin 
were compared with 4624 patients not treated with met-
formin. During the follow-up period of 2 years, the risk 
of death and the risk of hospitalization were assessed. 
Additionally, the relationship between metformin use 
and outcomes (time to death, time to HF hospitalization, 
and time to any hospitalization) was assessed using 
propensity score-matched analysis that consisted of 
29 baseline variables, and compared patients receiving 
metformin with patients not receiving metformin. Met-
formin therapy was associated with reduced mortality 
in comparison to therapy without metformin, in both 
unadjusted and propensity score-matched analysis. The 
risk of hospitalization for HF as well as all-cause hos-
pitalization was lower in patients receiving metformin 
compared with those not receiving metformin in unad-
justed analysis; however, in propensity score-matched 
analysis there was no statistically significant difference 
between groups [15].
Shah et al. investigated the use of metformin in 
patients with left ventricular ejection fraction (LVEF) 
below 40% (mean LVEF 24 ± 7%) and T2DM. Forty-two 
per cent of patients were in New York Heart Association 
(NYHA) class III and 45% in NYHA class IV. Ninety-nine 
patients who were on metformin therapy, as a mono-
therapy or in combination with other antidiabetic drugs, 
were compared with 302 patients using oral antidiabetic 
drugs other than metformin and/or insulin. During the 
6-month follow-up period, LVEF significantly improved 
in patients on metformin therapy compared with pa-
tients without metformin in their therapy. However, 
after adjustment for angiotensin-converting enzyme 
inhibitors (ACEI)/angiotensin receptor blockers (ARB) 
and B-blocker therapy the improvement in LVEF was 
nonsignificant. Patients on metformin therapy had 
significantly longer survival and lower risk of combined 
endpoint (all-cause mortality and the need for urgent 
(p = 0.011) of all-cause mortality, and a 39% lower risk 
(p = 0.010) of myocardial infarction (MI), in compari-
son to management with diet alone [9]. Moreover, in 
the post-trial 10-year follow-up of intensive glucose 
control, metformin proved to have a long-term effect 
on macrovascular outcomes, decreasing the risk of MI 
by 33% (p = 0.005) [10]. 
New evidence from large cardiovascular outcome 
trials (CVOTs), which showed CV benefits from the use 
of newer glucose-lowering drugs in patients with CVD 
or at very high/high CV risk, led to changes in the rec-
ommendations on the management of hyperglycaemia. 
The aim of this article is to review the current state 
of knowledge about the position of metformin in the 
treatment of patients with T2DM and HF.
Metformin in patients with type 2 diabetes 
mellitus and heart failure:  
a review of research studies
In the analysis of 1833 new users of oral antidiabetic 
agents with incident HF, metformin use, in mono-
therapy (n = 208) or in combination with sulfonylureas 
(n = 852), was compared with sulfonylurea monother-
apy (n = 773) (Tab. 1). During the 2.5-year follow-up, 
all-cause mortality and all-cause hospitalization, both 
at 1 year and at the end of the follow-up period, were 
evaluated. Metformin, alone or in combination with 
sulfonylureas, was associated with reduced 1-year 
and longer-term all-cause mortality in comparison to 
sulfonylurea monotherapy. On the other hand, there 
was no significant association between compared 
groups and all-cause hospitalization. In the composite 
outcome analysis fewer deaths and/or hospitalizations 
occurred in patients on metformin monotherapy and 
combination therapy when compared with sulfonyl-
urea monotherapy [11].
Sulfonylurea monotherapy was also used as a refer-
ence group in the observational study of 10,920 patients 
treated with metformin, sulfonylureas, and/or insulin, 
and hospitalized for the first time for HF. Metformin in 
monotherapy and in combination with sulfonylureas 
was associated with lower all-cause mortality compared 
with sulfonylureas in monotherapy. The results were 
similar in a separate analysis of patients using and not 
using insulin [12].
In the observational study of 16,417 patients with 
T2DM, discharged from a hospital with a major dis-
charge diagnosis of HF, the influence of insulin-sensitiz-
ing drugs on 1-year all-cause mortality, 1-year all-cause 
hospitalization, and HF hospitalization was assessed. 
Individuals treated with thiazolidinediones (n = 2226), 
metformin (n = 1861), as well as both thiazolidinediones 
and metformin (n = 261) had a lower risk of death com-
165






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































heart transplant) compared with patients without met-
formin in their therapy. In multivariate analysis there 
was no significant difference in survival between the 
analysed groups [16].
In the analysis from the PL-ASC registry (Polish Reg-
istry of Acute Coronary Syndromes), diabetic patients 
after acute coronary syndrome treated with percutane-
ous coronary intervention with no history of prior CVD 
were assessed. Patients treated with metformin were 
compared with patients not treated with metformin, 
before admission to a hospital. LVEF at discharge from 
the hospital was evaluated. The number of patients with 
LVEF below 40% was significantly lower in patients on 
metformin therapy in comparison to patients receiving 
antidiabetic drugs other than metformin (12% vs. 17%, 
p < 0.001) [17].
The impact of metformin use on patients with T2DM 
discharged from a hospital with a major diagnosis 
of acute HF was assessed in 835 participants. Dur-
ing a mean follow-up period of 2.4 years, long-term 
all-cause mortality was significantly lower in patients 
treated with metformin in comparison to patients 
without metformin in their therapy. In the multivariate 
analysis, metformin use was also significantly associated 
with lower all-cause mortality rates [18].
Metformin in patients with type 2 diabetes 
mellitus and heart failure:  
a review of guidelines
In the position statement from the Heart Failure As-
sociation (HFA) of the European Society of Cardiology 
(ESC) on type 2 diabetes mellitus and heart failure, 
metformin was presented as an antidiabetic drug that 
might be safe in heart failure and could be recom-
mended as a first-line therapy for patients with T2DM 
and HF, who have preserved or moderately reduced 
renal function. However, the document emphasizes 
the lack of randomized controlled trials of metformin 
use in patients with T2DM and HF [19].
According to the 2019 ESC Guidelines on diabetes, 
pre-diabetes, and cardiovascular diseases developed 
in collaboration with the EASD, metformin is safe at 
all stages of HF, reducing the risk of death and HF 
hospitalization in comparison to insulin and sulfonyl-
ureas. In the previous guidelines (2013) metformin 
was considered as a first-line therapy in patients with 
T2DM, independently of the patient’s cardiovascular 
profile [20]. However, there have been changes in the 
recommendations due to the recent publication of 
several CVOTs that indicate CV benefit from the use 
of glucagon-like peptide-1 (GLP-1) receptor agonists 
and SGLT2 inhibitors in patients with T2DM and CVD 

























































































































































































































































































































































































































































the current guidelines suggests that the choice of an-
tidiabetic drug in patients with T2DM should depend 
on the presence of CVD and CV risk. Thus, patients 
with T2DM and prevalent CVD or with very high/high 
CV risk should receive drugs with proven CV benefit, 
GLP-1 receptor agonists, or SGLT2 inhibitors, as a first 
choice in drug-naïve patients or as a second drug if the 
patient is already on metformin. On the other hand, in 
patients with T2DM without CVD or at moderate CV 
risk, metformin should be recommended as first-line 
therapy, especially in overweight individuals. In regard 
to the selection of glucose-lowering agents in patients 
with T2DM and HF or at high risk for HF, metformin 
and SGLT2 inhibitors are the first-line therapy. SGLT2 
inhibitors are recommended for the treatment of pa-
tients with T2DM and HF (class I of recommendation) 
because they seem to reduce HF-related endpoints, 
while metformin should be considered in these patients 
(class IIa of recommendation), which is based on ob-
servational studies and everyday clinical practice [21].
New evidence from CVOTs has also implied an im-
portant change in the 2018 Consensus Report by the 
American Diabetes Association (ADA) and the EASD 
on the Management of Hyperglycaemia in Type 2 
Diabetes. Since SGLT2 inhibitors have been proven 
to reduce hospitalization for HF in patients with ath-
erosclerotic cardiovascular disease in comparison to 
placebo, and they are recommended in patients with 
T2DM and coexisting HF or at risk for HF, as a part of 
glucose-lowering treatment. Nevertheless, metformin 
remains the preferred initial medication for the man-
agement of T2DM unless it is contraindicated or not 
tolerated. Subsequently, if HbA1c is above the target 
and HF predominates, a SGLT2 inhibitor with evidence 
of reducing HF progression should be added to the 
therapy [22].
Furthermore, in 2019 the Consensus Report on the 
Management of Hyperglycaemia in Type 2 Diabetes was 
updated by the ADA and the EASD, as a consequence 
of new research findings. The updated report suggests 
considering an initial combination therapy, composed 
of metformin and SGLT2 inhibitor, in new-onset dia-
betes mellitus if HF coexists, independently of baseline 
HbA1c or individualized HbA1c target, due to reduced 
hospitalization for HF, major adverse cardiovascular 
events, and cardiovascular death, especially in pa-
tients with reduced left ventricular ejection fraction 
(LVEF < 45%) [23].
Discussion
The impact of metformin therapy on clinical outcomes 
in patients with T2DM and coexisting HF has been as-
sessed in large observational studies. In this review, 8 
observational studies were included (Table 1). Despite 
an extensive literature search, no randomized con-
trolled trials evaluating the effects of metformin therapy 
in patients with T2DM and HF were identified. Indeed, 
the execution of a randomized controlled trial could be 
difficult because of the common use of metformin in 
patients with HF [24, 25]. For many years metformin 
was contraindicated in patients with HF due to the 
risk of metformin-associated lactic acidosis. However, 
the incidence of lactic acidosis in clinical practice has 
proved to be very low and the United States Food 
and Drug Administration has removed congestive HF 
from the boxed warning section of metformin [26]. 
Nevertheless, hypoxic states such as the setting of acute 
congestive HF remain contraindications for metformin 
use, especially when hypoperfusion and hypoxaemia 
coexist [27]. At the same time, in the Polish Summary 
of Product Characteristics, HF is consistently one of 
the main contraindications of metformin, although it 
should be assumed that this refers to acute states [28].
Data from available studies have shown that met-
formin use, assessed in monotherapy or in combination 
with other oral antidiabetic drugs and/or insulin, in 
patients with T2DM and HF, was associated with im-
proved clinical outcomes when compared with other 
oral antidiabetic agents, insulin, or lifestyle manage-
ment. Based on this result, metformin is considered to 
be a safe drug in heart failure and remains the first-line 
treatment in patients with heart failure and diabetes, 
which is supported by clinical experience [22]. However, 
the safety of metformin in the results of observational 
studies might be a consequence of its cautious use in 
patients with HF due to its contraindications. Addition-
ally, when metformin is compared to other antidiabetic 
agents, there is a probability that the outcomes are the 
consequence of a harm effect of the comparator agent. 
This is the reason why there is a need for randomized 
controlled trials to show not only the safety of metfor-
min but also its beneficial effect on the onset and the 
course of heart failure.
SGLT2 inhibitors have emerged as antidiabetic 
drugs that significantly reduce HF hospitalization and 
CV death in patients with T2DM and high CV risk, 
when compared with placebo in large CVOTs [29, 30]. 
Moreover, trials on dapagliflozin and empagliflozin 
showed that SGLT2 inhibitors reduce HF hospitaliza-
tion and CV death in patients with HF, not only when 
diabetes coexists but also in patients without diabetes 
[31]. Therefore, the position of metformin in the treat-
ment of patients with T2DM and HF has changed. Cur-
rently, ESC Guidelines recommend SGLT2 inhibitors in 
patients with T2DM and HF or at high risk for HF, as 
a first choice in drug-naïve patients or as a second drug 
if the patient is already on metformin [21]. However, 
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this statement is not confirmed by any randomized 
controlled clinical trial, and it has not been proven 
that starting glucose-lowering treatment with SGLT2 
inhibitors, instead of metformin, is beneficial. In CVOTs, 
SGLT2 inhibitors were added to the standard therapy in 
which more than 70% of patients had already received 
metformin at baseline. Additionally, hospitalization due 
to HF was a secondary endpoint in each trial; thus, 
groups of patients with HF were not thoroughly char-
acterized at baseline and were relatively small. Finally, 
there are no clinical trials on SGLT2 inhibitors that show 
a reduction of CV risk in patients with HbA1c < 7%, be-
cause all of the participants of CVOTs had HbA1c > 7% 
at baseline [22].
Conclusions
According to the Summary of Product Characteristics, 
metformin is contraindicated in patients with HF. 
However, metformin is the most frequently used oral 
antidiabetic drug in T2DM; thus, a great number of 
patients with HF receive metformin despite the con-
traindications. The analysis of data from observational 
studies and meta-analyses shows that metformin has 
a favourable effect in patients with T2DM and HF. 
Modification of the Summary of Product Characteristics 
should be considered after performing randomized 
controlled trials on metformin treatment in patients 
with T2DM and HF.
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